This project addresses ethical and policy issues regarding current genetic susceptibility testing for late-onset Alzheimer disease. It also addresses the ethical aspects of ongoing autosomal dominant testing in families with early-onset Alzheimer disease. The project's Community Advisory Board and National Study Group will take up these tasks: examine current testing developments in AD genetics, their presymptomatic applicability, and clinical usefulness; consider costs of testing, potential testing pool, and justice in access to testing; address potential impact of susceptibility testing on private long- term care insurance industry; develop ethics guidelines for apolipoprotein (ApoE) susceptibility testing and APP autosomal dominant mutation testing; develop recommendations for the Alzheimer's Association in ensuring public understanding of test developments. In addition, a pilot questionnaire study of population attitudes toward ApoE susceptibility testing, to be implemented in Chicago, is included. As the introduction to this proposal indicates, this project is now urgent and timely, and proceeds in collaboration with the National Alzheimer's Association.
| Post, S G (1999) Future scenarios for the prevention and delay of Alzheimer disease onset in high-risk groups. An ethical perspective. Am J Prev Med 16:105-10 |
| Post, S G; Whitehouse, P J; Binstock, R H et al. (1997) The clinical introduction of genetic testing for Alzheimer disease. An ethical perspective. JAMA 277:832-6 |
| Post, S G (1996) On not jumping the gun: ethical aspects of APOE gene testing for Alzheimer's disease. Ann N Y Acad Sci 802:111-9 |
